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Over the last three decades, it has become clear that the role of vitamin D goes beyond 
the regulation of calcium homeostasis and bone health. An important extraskeletal effect 
of vitamin D is the modulation of the immune system. In the context of autoimmune dis-
eases, this is illustrated by correlations of vitamin D status and genetic polymorphisms in 
the vitamin D receptor with the incidence and severity of the disease. These correlations 
warrant investigation into the potential use of vitamin D in the treatment of patients with 
autoimmune diseases. In recent years, several clinical trials have been performed to 
investigate the therapeutic value of vitamin D in multiple sclerosis, rheumatoid arthritis, 
Crohn’s disease, type I diabetes, and systemic lupus erythematosus. Additionally, a 
second angle of investigation has focused on unraveling the molecular pathways used 
by vitamin D in order to find new potential therapeutic targets. This review will not only 
provide an overview of the clinical trials that have been performed but also discuss the 
current knowledge about the molecular mechanisms underlying the immunomodulatory 
effects of vitamin D and how these advances can be used in the treatment of autoim-
mune diseases.
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iNTRODUCTiON
Autoimmune diseases, including rheumatoid arthritis (RA), multiple sclerosis (MS), and Crohn’s 
disease (CD), result from an aberrant activation of the immune system, whereby the immune 
response is directed against harmless self-antigens. This results in inflammation, tissue damage, 
and loss of function of the affected organs or joints. With the increasing prevalence of autoimmun-
ity in the Western countries (1), the societal burden of these diseases also increases. Although the 
treatment of autoimmune diseases has improved due to the development of so-called biologics, like 
tumor necrosis factor alpha (TNFα) inhibitors, a large proportion of patients are still not adequately 
responding to these treatments (2). Therefore, it is still important to improve current therapies or to 
uncover new treatment options.
In this context, the immunomodulatory effects of vitamin D provide opportunities to enhance 
the treatment of autoimmune diseases. First, given the high prevalence of vitamin D deficiency in 
patients suffering from autoimmunity, vitamin D supplementation might decrease disease severity or 
augment the therapeutic effect of current medication. Second, knowing the molecular mechanisms 
underlying the immunomodulatory effects could lead to the discovery of new potential therapeutic 
FiGURe 1 | vitamin D metabolism. The metabolic pathway of vitamin D. Red arrows indicate inhibition, and green arrows indicate induction.
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targets. Therefore, this review will explore the advances that 
have been made in both clinical trials and molecular studies. 
In addition, it will give an overview of the challenges that still 
remain before the immunomodulatory effects of vitamin D can 
be utilized in clinical practice.
viTAMiN D MeTABOLiSM, SiGNALiNG, 
AND FUNCTiON
Vitamin D, or cholecalciferol, is a secosteroid hormone that can be 
obtained from dietary sources, but that is predominantly synthe-
sized in the skin from 7-dehydroxycholesterol in response to UV 
light (Figure 1). Cholecalciferol is bound by vitamin D-binding 
protein (DBP) and transported to the liver. In the liver, various 
cytochrome p450 (Cyp) vitamin D hydroxylases convert chole-
calciferol into 25(OH)D3. Cyp2R1 is considered to be the primary 
25-hydroxylase responsible for this process. Subsequently, DBP 
transports 25(OH)D3 to the kidneys, where the 1α-hydroxylase 
Cyp27B1 converts 25(OH)D3 into 1,25(OH)2D3. 1,25(OH)2D3, 
also called calcitriol, is the active vitamin D metabolite. To control 
calcitriol concentrations, the 24-hydroxylase Cyp24A1 hydroxy-
lates 25(OH)D3 or 1,25(OH)2D3 at C-24, yielding the less active 
metabolites 24,25(OH)2D3 and 1,24,25(OH)3D3, respectively (3). 
The level of 1,25(OH)2D3 is therefore mainly determined by the 
balance between Cyp27B1 and Cyp24A1. Two proteins that are 
important for regulating this balance are fibroblast growth factor 
23 (FGF23) and parathyroid hormone (PTH). FGF23 shifts the 
balance toward Cyp24A1 and therefore inactivation of vitamin D 
signaling, and is induced by high concentrations of 1,25(OH)2D3 
and low serum phosphate. On the other hand, PTH favors the bal-
ance toward Cyp27B1 and activation of vitamin D signaling. PTH 
is inhibited by high concentrations of 1,25(OH)2D3 and induced 
by low serum calcium (3) (Figure 1).
1,25(OH)2D3 initiates its signaling cascade by binding to the 
vitamin D receptor (VDR), which is a nuclear receptor that acts 
as a transcription factor. VDR binds to vitamin D responsive 
elements (VDREs) in the DNA, mostly to so-called DR3-type 
VDREs that are characterized by two hexameric core binding 
motifs separated by three nucleotides. In the absence of ligand, 
VDR is mostly bound to non-DR3-type VDREs and is associated 
with corepressor proteins. When 1,25(OH)2D3 binds to VDR, 
this induces a conformational change leading to the formation 
of two new protein interaction surfaces. One is for binding with 
heterodimeric partners to facilitate specific DNA binding, such 
as retinoid X receptor (RXR), and the other is for recruitment 
of co-regulatory complexes that will exert the genomic effects of 
VDR (4). Furthermore, there is a shift in binding to primarily 
DR3-type VDREs (5). Interestingly, although RXR has multiple 
binding partners, specifically with VDR it will bind to the DR3-
type elements. This indicates that the heterodimerization of VDR 
and RXR is important for functioning of the VDR (6). However, 
research in colorectal cancer cells has shown that 25% of the VDR 
binding sites are not enriched for RXR (7). No direct data on colo-
calization of VDR and RXR in immune cells have been reported, 
although Handel et al. found a significant overlap between VDR 
3Dankers et al. Vitamin D in Autoimmunity
Frontiers in Immunology | www.frontiersin.org January 2017 | Volume 7 | Article 697
in CD4+ T cells and RXR in a promyelocytic leukemia cell line (8). 
Therefore, it is currently unknown whether the rate of VDR/RXR 
colocalization differs between cell types. Also, the functional 
consequence of VDR binding with or without RXR remains to 
be understood.
The best known function of 1,25(OH)2D3 is the maintenance 
of calcium homeostasis by facilitating the absorption of calcium 
in the intestine. However, in the presence of low 1,25(OH)2D3 
levels, calcium will be mobilized from the bone rather than the 
intestine. If these conditions are prolonged, this may lead to 
osteomalacia and rickets, both well-known clinical signs of vita-
min D deficiency. An overview of the current knowledge on the 
role of vitamin D signaling in calcium homeostasis was recently 
given by Carmeliet et al. and will not be discussed here (9). The 
first hint that vitamin D might also be important for extraskeletal 
health came from mycobacterial infections such as tuberculosis, 
in which vitamin D was used as a treatment before antibiotics 
were discovered (10). The discovery that the VDR is expressed 
in almost all human cells has further increased the attention 
for the extraskeletal effects of vitamin D. As a result, vitamin D 
deficiency has now been linked to not only bone health but also, 
for example, cancer, cardiovascular diseases, and autoimmune 
diseases (9).
viTAMiN D AND AUTOiMMUNe DiSeASeS
Since the discovery of the VDR on blood lymphocytes (11, 12), the 
effects of vitamin D on the immune system and immune-related 
diseases became the subject of a large number of studies. In this 
context, it was discovered that supplementation with 1,25(OH)2D3 
could prevent both the initiation and progression of experimental 
autoimmune encephalomyelitis (EAE) and collagen-induced 
arthritis (CIA), experimental models of MS and RA, respectively 
(13–15). In addition, VDR deficiency aggravated arthritis severity 
in human TNFα transgenic mice (16). Similarly, vitamin D defi-
ciency increased enterocolitis severity in IL-10 knock-out (KO) 
mice, which are used as a model system for inflammatory bowel 
diseases (IBDs). Treatment with 1,25(OH)2D3 decreased disease 
symptoms in both the IL-10 KO mice and in the dextran sulfate 
sodium (DSS)-induced colitis model (17, 18). Finally, treatment 
with 1,25(OH)2D3 reduced the incidence of diabetes in non-obese 
diabetic (NOD) mice (19, 20) and the severity of systemic lupus 
erythematosus (SLE) in MRL/1 mice (21).
These studies in experimental autoimmune models underscore 
the need to examine whether there is a protective role for vitamin 
D in human autoimmune diseases. In the last few decades, numer-
ous studies have investigated the link between vitamin D and the 
incidence and severity of autoimmune diseases. One of the first 
indications was the correlation between increasing MS preva-
lence and increasing latitude, and consequently with decreasing 
sunlight exposure. Exceptions to this gradient can at least par-
tially be explained by genetic variants (like the HLA-DRB1 allele) 
or lifestyle differences, such as high fish consumption (22). The 
relation between latitude and disease prevalence was also found 
for other autoimmune diseases such as type I diabetes mellitus 
(T1D) and IBD (23, 24). Further strengthening the link between 
sun exposure and autoimmunity is the finding that the risk of 
developing MS is correlated with the month of birth, with for the 
northern hemisphere a higher risk in April and a lower risk in 
October and November (25, 26). Importantly, this correlation can 
only be found in areas where the UV exposure changes during 
the year (25).
Next to UV exposure, vitamin D can also be obtained from 
dietary sources and supplements. A meta-analysis by Song 
et al. found that the incidence of RA is inversely correlated with 
vitamin D intake, both when considering dietary intake and 
supplements or supplements alone (27). In addition, vitamin 
D supplementation in early childhood might reduce the risk of 
developing T1D up to 30% depending on the supplementation 
frequency (28, 29). Also the effect of maternal vitamin D intake 
on the risk of T1D in the offspring has been investigated, but due 
to the limited amount of studies there is currently not sufficient 
evidence to prove a correlation (29).
Investigating the correlation between vitamin D intake and 
prevalence of autoimmunity is challenging because the measure-
ments of dietary intake and UV exposure are often based on 
estimations. Therefore, it might be more useful to analyze the 
correlation between the serum 25(OH)D3 level and autoimmun-
ity. Indeed, in many autoimmune diseases, patients have a lower 
serum 25(OH)D3 than healthy controls (30–36). In addition, 
patients with a lower 25(OH)D3 level are implicated to have higher 
disease activity (32, 35, 37). Although it is not clear whether the 
lower 25(OH)D3 level also increases the risk of autoimmunity, 
the study by Hiraki et al. suggested that there is a strong correla-
tion between the risk of developing RA and the 25(OH)D3 level 
between 3 months and 4 years before diagnosis (38). It should be 
noted that all these studies merely demonstrate correlations, so it 
is still under debate whether the low 25(OH)D3 level is the cause 
or the result of the autoimmune disease.
Another line of evidence that indicates a role for vitamin D in 
human autoimmunity is the correlation with polymorphisms in 
the VDR. There are four well-known VDR polymorphisms that 
have been extensively studied for their potential role in autoim-
munity: ApaI, BsmI, TaqI, and FokI. All of these polymorphisms 
have been associated with the risk of developing an autoimmune 
disease, although it differs between diseases and polymorphisms 
whether it is protective or a risk factor. Also, ethnicity plays a role 
in the correlation between the polymorphisms and autoimmune 
diseases (39–47).
In summary, autoimmune diseases are correlated with 25(OH)
D3 serum levels, vitamin D intake, UV exposure, and VDR 
polymorphisms. Furthermore, 1,25(OH)2D3 suppresses disease 
in experimental autoimmune models. Although these data do 
not prove a causal relationship between vitamin D and autoim-
mune diseases, they warrant further investigation into whether 
at-risk individuals and patients could benefit from vitamin D 
supplementation.
viTAMiN D AS A THeRAPeUTiC AGeNT  
iN HUMAN AUTOiMMUNe DiSeASeS
Despite the beneficial effects of 1,25(OH)2D3 supplementation in 
experimental autoimmune models, the application of vitamin D 
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derivatives in clinical practice is currently limited to topical use 
for the treatment of psoriasis (48). The systemic use of vitamin 
D in the treatment of other autoimmune diseases is still under 
investigation. Table 1 gives an overview of the placebo-controlled 
clinical trials investigating the effect of vitamin D supplementa-
tion in autoimmune diseases other than psoriasis. Here, we dis-
cuss these trials and what this means for the therapeutic potential 
of vitamin D in each of these autoimmune diseases.
Multiple Sclerosis
In the field of MS, several trials have been performed in which 
cholecalciferol was given to the patients, but the results are 
contradictory. Beneficial effects of cholecalciferol supplementa-
tion that have been reported include decrease in Expanded 
Disability Status Scale (EDSS), decrease in MRI lesions, increased 
functionality, and reduced relapse rates (49, 51). Importantly, 
cholecalciferol has an added effect when used as a supplement 
to interferon β (IFNβ) treatment (51). On the other hand, two 
other trials reported no difference in any of these parameters (50, 
52). Vitamin D supplementation might also be important in the 
pre-MS stage, since cholecalciferol supplementation decreased 
the conversion rate of optic neuritis to chronic MS (53).
Due to the small sample size (no more than 35 patients/group) 
of these trials, it is difficult to draw conclusions from these data. 
Although the effect of cholecalciferol on conversion to chronic 
effect appears promising, this was only one study with 13 treated 
patients and 11 placebo controls. Therefore, more research is 
necessary to determine whether therapy with cholecalciferol is 
beneficial for MS patients.
Rheumatoid Arthritis
Despite the beneficial effect of 1,25(OH)2D3 supplementation 
on experimental arthritis (15), there are to date only three 
randomized trials investigating the effect of supplementation on 
disease activity in RA. Although the studies performed by Salesi 
and Farajzadegan and Dehghan et  al. suggested a beneficial 
effect on disease activity and relapse rate, respectively, neither 
results reach statistical significance (54, 55). However, Dehghan 
et al. pointed out that for every 10 patients treated with cholecal-
ciferol, relapse would be prevented in one patient. Considering 
the costs and safety profile of cholecalciferol supplementation, 
this might be worth following up. Ergocalciferol, the less potent 
fungal equivalent of human cholecalciferol, had no effect on 
disease activity and was associated with worse patient-related 
health assessments (56). Similar to studies in MS, the major 
limitation in the three RA studies is the group size, which limits 
the power of the analyses. Therefore no definitive conclusion can 
be drawn yet whether vitamin D can be used as a therapeutic 
agent in RA.
Crohn’s Disease
Crohn’s disease is a subtype of the IBDs and is investigated 
intensively for the effect of vitamin D supplementation. However, 
the difficulty with this disease is that the intestinal inflammation 
may lead to decreased absorption of the supplemented vitamin D. 
Nevertheless, for adult patients, cholecalciferol supplementation 
might reduce the risk of relapses, although the difference does 
not reach statistical significance (p = 0.06) (57). Correspondingly, 
cholecalciferol prevented further increase of intestinal perme-
ability, which may be an early marker of relapse (59). This is 
even more pronounced when the patients are stratified based on 
their serum 25(OH)D3 level. Additionally, patients with a serum 
level above 75  nmol/L have significantly lower serum levels of 
C-reactive protein (CRP, a marker of inflammation) and a non-
significant decrease in disease activity as measured with Crohn’s 
Disease Activity Index (59). These studies used 1,200–2,000 IU 
cholecalciferol daily in adults, but in children there is no differ-
ence in disease activity between supplementing 400 and 2,000 IU 
daily despite a serum 25(OH)D3 level that is 25 nmol/L higher in 
the latter group (58).
When compared to RA and MS, the results for adult CD are 
more consistently showing a beneficial effect of cholecalciferol 
treatment. Since group sizes are again small, more research is 
required to confirm these data.
Type i Diabetes Mellitus (T1D)
In contrast to the other autoimmune diseases where cholecalcif-
erol supplementation is investigated, in T1D almost all trials use 
1,25(OH)2D3 or an analog. Both forms appear to delay, but not 
prevent, the progression of β cell destruction in three studies (60, 
63, 64). On the other hand, no effect of 1,25(OH)2D3 on T1D 
was observed in studies performed by Bizzarri et  al. (61) and 
Walter et al. (62). This lack of effect could be due to the low level 
of remaining β cell function at the start of the study, suggesting 
that the therapeutic window for vitamin D supplementation is 
in the earliest phases of the disease. The study by Li et al. found 
that the protective effect is only visible when the disease duration 
was less than 1 year, supporting this hypothesis (60). In T1D, the 
beneficial effects of 1,25(OH)2D3 may lie more in the prevention 
of disease onset (28, 29) than in the treatment of disease, since the 
destruction of β cells cannot be reversed.
Systemic Lupus erythematosus
Vitamin D supplementation in SLE might even be more relevant 
than in the other autoimmune diseases, since 80% of the patients 
is sensitive for sunlight and therefore protect themselves against 
UV exposure (68). Two studies supplementing either 2,000  IU 
daily or 50,000 IU weekly demonstrated decreasing disease activ-
ity score, auto-antibody levels, and fatigue (65, 66). Conversely, the 
type I interferon (IFN) signature was unchanged after 12 weeks 
of 2,000 or 4,000 IU cholecalciferol in another study (67). Since 
this study was performed in patients with inactive disease, had 
a short supplementation period, and the signature was based on 
the expression of only three genes, it remains to be determined 
whether cholecalciferol supplementation truly does not affect the 
complete IFN signature in patients with active disease.
Systemic lupus erythematosus is the only autoimmune disease 
is which a larger study was done, with 158 cholecalciferol-treated 
patients and 89 placebo controls (65). The promising results in 
this clinical trial await further confirmation before vitamin D can 
be used therapeutically in these patients.
(Continued)
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TABLe 1 | Overview of randomized controlled trials with vitamin D supplementation in autoimmune diseases.
Trial Disease Trial design inclusion criteria Groups Supplementation 
dosage
Supplemental 
calcium
Other medication Baseline 
25(OH)D3 
in treated 
group 
(nmol/L)
endpoint 
25(OH)D3 in 
treated group 
(nmol/L)
Main clinical findings
Burton  
et al. (49)
Multiple 
sclerosis  
(MS)
Open-
label RCT, 
52 weeks
MS without a 
relapse within 
60 days
N = 25 
cholecalciferol, 
N = 24 placebo
Dose escalation: up 
to 280,000 IU/week 
in 23 weeks, stay 
6 weeks, then reduce 
to 0 in 20 weeks, 
then 3 weeks without
1,200 mg daily Continuation of MS 
medication, placebo-
treated patients could 
take up to 4,000 IU 
cholecalciferol and 
supplemental calcium 
if desired. In case 
of relapse, patients 
received steroids as 
judged by the treating 
physician
80 Up to 
400 nmol/L 
after the peak 
of dosage, 
200 nmol/L at 
the end of the 
trial
Lower proportion of patients 
with an increase in EDSS at the 
end of the trial
EDSS 0–6.5 Trend toward reduced relapse 
rate
Serum 25(OH)
D3 < 150 nmol/L
Mosayebi 
et al. (50)
MS Double-
blind RCT, 
6 months 
(October–
March)
MS with a relapse  
in the last year
More than three 
lesions on MRI.
EDSS 0–3.5
N = 28 
cholecalciferol, 
N = 34 placebo
300,000 IU monthly 
(intramuscular)
No IFNB-1a 25 150 No effect on EDSS
No effect on Gd-enhancing 
lesions
Soilu-
Hänninen 
et al. (51)
MS Double-
blind RCT, 
12 months
RRMS with at 
least 1 month 
IFNB-1b treatment
Serum 25(OH)
D3 < 85 nmol/L
N = 34 
cholecalciferol, 
N = 32 placebo
20,000 IU weekly No IFNB-1b 54 110 Reduced number of 
Gd-enhancing lesions, but no 
effect on other MRI parameters
Trend toward reduced EDSS
Kampman 
et al. (52)
MS Double-
blind RCT, 
96 weeks
MS with an 
EDSS < 4.5
N = 35 
cholecalciferol, 
N = 33 placebo
20,000 IU weekly 500 mg daily 46% of patients in 
both groups were 
treated with IFNβ, 
3% with glatiramer 
acetate and 3% in the 
placebo group with 
natalizumab
55 123 No effects on EDSS, relapse 
rate, function, or fatigue
Derakhshandi 
et al. (53)
MS Double-blind 
pilot RCT, 
12 months
Optic neuritis 
patients without  
MS
N = 13 
cholecalciferol, 
N = 11 placebo
50,000 IU weekly, 
when reaching 
serum 25(OH)D3 of 
250 nmol/L switch to 
a maintenance dose
No 3 × 1 g 
methylprednisolone/
day i.v., then oral 
prednisolone
38 Unknown Decreased incidence rate ratio 
of demyelinating plaques
Reduced risk of progression 
to MS
Salesi and 
Farajzadegan 
(54)
Rheumatoid 
arthritis (RA)
Double-
blind RCT, 
12 weeks
RA with 
DAS28 > 3.2
At least 24 weeks 
MTX treatment
N = 50 25(OH)
D3, N = 48 
placebo
50,000 IU weekly No MTX 107 125 Modest, non-significant, 
improvement in tender joint 
count, swollen joint count, 
ESR, and VAS
Prednisone, HCQ, and 
CQ were allowed
Trial Disease Trial design inclusion criteria Groups Supplementation 
dosage
Supplemental 
calcium
Other medication Baseline 
25(OH)D3 
in treated 
group 
(nmol/L)
endpoint 
25(OH)D3 in 
treated group 
(nmol/L)
Main clinical findings
Dehghan 
et al. (55)
RA Double-
blind RCT, 
6 months
RA in remission for 
at least 2 months
N = 40 
cholecalciferol, 
N = 40 placebo
50,000 IU weekly No Prednisone, MTX, and 
HCQ allowed
<75 Unknown Non-significant decrease in 
relapse rate
Serum 25(OH)
D3 < 75 nmol/L
Hansen  
et al. (56)
RA Double-
blind RCT 
12 months
RA
Serum 25(OH)D3 
between 15.25 
and 62.25 nmol/L
N = 11 
cholecalciferol, 
N = 11 placebo
4 weeks: 50,000 IU 
3× weekly
11 months: 50,000 IU 
2× monthly
When serum was 
below 62.5 nmol/L: 
50,000 IU weekly for 
8 weeks
500 mg 3× 
daily
SPF65 63 75 (after 
2 months)
No effects on DAS28, HAQ, or 
physician global assessment 
of RA
Non-significant increase in pain
Increased patient assessment 
of global health and patient 
global assessment of RA
Jørgensen 
et al. (57)
Crohn’s 
disease (CD)
Double-blind 
RCT, 1 year
CD in remission 
(CDAI < 150) for 
at least 4 weeks
N = 46 
cholecalciferol, 
N = 48 placebo
1,200 IU daily 1,200 mg daily Azathioprine (39–44% 
of participants)
70 95 Trend toward reduced relapse 
(hazard ratio of 0.44)
Wingate  
et al. (58)
CD Double-
blind RCT, 
6 months
Children with 
quiescent CD
N = 352,000 IU 
cholecalciferol, 
N = 34,400 IU 
cholecalciferol
400 or 2,000 IU 
daily depending on 
randomization
No Multivitamins (without 
vitamin D)
63 70 (400 IU) or 
86 (2,000 IU)
No difference between the 
groups in CDAI, ESR, or CRP
Normal inflammatory 
bowel diseases 
(IBD) medication 
(36% 5-ASA, 57% 
immunomodulator, 
30% biologics)
Raftery  
et al. (59)
CD Double-
blind RCT, 
3 months
Adults with 
CD in remision 
(CDAI < 150) and 
stable therapy for 
3 months
N = 13 
cholecalciferol, 
N = 14 placebo
2,000 IU daily Only when 
already on it for 
bone health
Normal IBD 
medication (51% 
5-ASA, 67% 
immunomodulator, 
7% anti-TNFα)
70 90 Intestinal permeability was 
stable in the treated group, but 
increased in the placebo group
Reduced CRP, increased QoL 
and trend toward decreased 
CDAI in patients with serum 
25(OH)D3 > 75 nmol/L
Li et al. (60) T1D Prospective 
RCT, 
12 months
LADA patients 
with diagnosis 
<5 years
N = 17 
alfacalcidol, 
N = 18 
unsupplemented
0.25 µg twice daily No Insulin therapy in both 
groups
63 Unknown Stable FCP while decline in 
control group, same trend for 
PCP. Especially pronounced 
when disease duration <1 year
(Continued)
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TABLe 1 | Continued
Trial Disease Trial design inclusion criteria Groups Supplementation 
dosage
Supplemental 
calcium
Other medication Baseline 
25(OH)D3 
in treated 
group 
(nmol/L)
endpoint 
25(OH)D3 in 
treated group 
(nmol/L)
Main clinical findings
Bizzarri  
et al. (61)
T1D Double-
blind RCT, 
24 months
Recent-onset T1D N = 15 calcitriol, 
N = 12 placebo
0.25 µg daily No Insulin therapy in both 
groups
<50 +3.9% After 12 months, the decline 
in FCP is slower in treated 
group, but not anymore after 
24 months
Walter  
et al. (62)
T1D Double-
blind RCT, 
18 months
Adults with recent-
onset T1D
N = 20 calcitriol, 
N = 18 placebo
0.25 µg daily No Insulin therapy in both 
groups
25 pg/mL 
[1,25(OH)
D3]
30 pg/mL 
[1,25(OH)D3]
No changes in C-peptide or 
insulin dose
Gabbay  
et al. (63)
T1D Double-
blind RCT, 
18 months
Patients with 
recent-onset T1D 
(age >7 years)
N = 17 
cholecalciferol, 
N = 19 placebo
2,000 IU daily No Insulin therapy in both 
groups
65 150 Decreased progression to 
undetectable C-peptide
Enhanced stimulated C-peptide 
after 12 months
Decreased decay of stimulated 
C-peptide after 18 months
Ataie-Jafari 
et al. (64)
T1D Single-
blind RCT, 
6 months
Patients with 
recent-onset T1D
N = 29 
alfacalcidol, 
N = 25 placebo
0.25 µg once daily, or 
twice if blood calcium 
levels allowed it
No Insulin therapy in both 
groups
32.5 Unknown Better preservation of 
C-peptide and lower insulin 
dose. Stronger effect in males 
than in females
Abou-Raya 
et al. (65)
Systemic lupus 
erythematosus 
(SLE)
Double-
blind RCT, 
12 months
SLE with SLEDAI 
>1
N = 158 
cholecalciferol, 
N = 89 placebo
2,000 IU daily Yes, unknown 
dose
6% corticosteroids, 
80% antimalarials, 
26% AZA, 27% ACE 
inhibitors/ARB
50 98 Decrease in SLEDAI and ESR
Serum 25(OH)
D3 < 75 nmol/L
Lima  
et al. (66)
SLE Double-
blind RCT, 
24 weeks
Juvenile onset 
SLE
N = 20 
cholecalciferol, 
N = 20 placebo
50,000 IU weekly No Unknown, but stable 
during trial
50 78 Decrease in SLEDAI, trend 
to decrease in ECLAM and 
decrease of fatigue related to 
social life
SLEDAI < 12
Aranow  
et al. (67)
SLE Double-
blind RCT, 
12 weeks
Adult SLE with 
IFNα signature
N = 184,000 IU 
cholecalciferol, 
N = 172,000 IU 
cholecalciferol, 
N = 19 placebo
2,000 IU or 4,000 IU 
daily
No Unknown 28 75 No difference in IFN signature 
(based on three genes) or 
disease activityStable inactive 
disease
Anti-dsDNA 
positive
Serum 25(OH)
D3 < 50 nmol/L
ASA, 5-aminosalicylzuur (sulfasalazine); CDAI, Crohn’s disease activity index; CQ, chloroquine; CRP, C-reactive protein; ECLAM, European consensus lupus activity measurement; EDSS, Expanded Disability Status Scale; ESR, 
erythrocyte sedimentation rate; FCP, fasting c-peptide; Gd, gadolinium; HAQ, health assessment questionnaire; HCQ, hydroxychloroquine; IU, International Units; LADA, latent autoimmune diabetes in adults; MTX, methotrexate; PCP, 
C-peptide after 75 g glucose; QoL, quality of life; RCT, randomized controlled trial; RRMS, relapsing-remitting multiple sclerosis; SLEDAI, systemic lupus erythematosus disease activity index; DAS28, disease activity score for 28 joints; 
VAS, visual analog scale.
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FiGURe 2 | The anti-inflammatory effects of 1,25(OH)2D3 on cells of the immune system. An overview of the anti-inflammatory effects of 1,25(OH)2D3 on the 
cells of the immune system in autoimmunity. Red dots represent pro-inflammatory cytokines, while green dots represent anti-inflammatory cytokines. Red arrows 
indicate decreased differentiation, and green arrows indicate increased differentiation. References: CD8+ T cells (79–81); innate lymphoid cells (82–86); 
unconventional T cells (87–89); B cells (75, 90–96); dendritic cells (97–103); macrophages (104–108); CD4+ T cells (109–125).
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iMMUNe MODULATiON BY viTAMiN D
In addition to exploring the potential of therapeutic vitamin D 
supplementation, there has been a great deal of research toward 
the working mechanisms of 1,25(OH)2D3 in cells of the immune 
system. Since autoimmune diseases are characterized by an 
overactive immune response, it seems logical that the beneficial 
effects of vitamin D on autoimmunity are due to effects on the 
immune system. Furthermore, virtually all immune cells express 
the VDR, making them susceptible to 1,25(OH)2D3-mediated 
modulation (11, 12, 69, 70). Various immune cells, including 
monocytes, dendritic cells, macrophages, B cells, and T cells, 
also have the capability to convert 25(OH)D3 into 1,25(OH)2D3 
(71–78). This allows for local regulation of the concentration 
of 1,25(OH)2D3 at the site of inflammation and illustrates an 
important role for the cells of the immune system in the systemic 
effects of vitamin D.
Therefore, insight into how 1,25(OH)2D3 modulates the 
immune system could uncover new therapeutic targets in auto-
immune diseases. Here, we discuss the effects of vitamin D on 
various cell types involved in the immune response, the current 
knowledge about the underlying mechanisms, and what this 
means for the therapeutic potential of vitamin D in autoimmun-
ity (Figure 2).
Dendritic Cells
Dendritic cells are antigen-presenting cells (APCs), which means 
that their main function is to take up foreign antigens and pre-
sent them as peptides to T cells on the human leukocyte antigen 
(HLA) molecules. DCs are predominantly found in an immature 
state in peripheral tissues such as the skin, gut, and lungs, where 
they probe the surroundings for potential pathogens. Upon 
encountering a foreign antigen, they mature and migrate to the 
lymphoid tissues to stimulate antigen-specific T cells. Depending 
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on the cytokines secreted by the DC, the T cell will differentiate 
into an effector cell with appropriate pro- or anti-inflammatory 
properties. Through these actions, APCs are crucial in initiating 
effective adaptive immune responses against pathogens, and also 
for maintaining self-tolerance and immune homeostasis.
The important role of DCs in autoimmune pathogenesis is 
illustrated in experimental autoimmune models, where deletion 
of specific DC subtypes ameliorates, or even prevents disease 
onset (126–129). In addition, APCs, including DCs and also 
macrophages and B cells, are associated with human autoim-
munity through the correlation between specific HLA alleles 
and the risk of developing an autoimmune disease. For example, 
HLA-DRB1*15:01 is associated with an increased risk for MS 
(130), while HLA-DRB1*04:01 confers a greater susceptibility to 
RA (131).
Dendritic cells differentiated in  vitro from monocytes or 
bone marrow cells in the presence of 1,25(OH)2D3 will remain 
in an immature-like tolerogenic state. This is characterized by 
decreased production of pro-inflammatory factors like IL-12 
and TNFα and increased anti-inflammatory IL-10 production. 
These tolerogenic DCs (tDCs) are less capable of promoting 
proliferation and cytokine production of pro-inflammatory T 
cells, while they induce the differentiation of T regulatory (Treg) 
cells (97–99). Furthermore, they specifically induce apoptosis in 
autoreactive T cells, while not affecting proliferation of other T 
cells (132). Of note, 1,25(OH)2D3 can only induce this tolerogenic 
phenotype in DCs when it is added before their maturation. Once 
a maturation stimulus like lipopolysaccharide (LPS) is present or 
when the cells have already matured, the effects of 1,25(OH)2D3 
on DCs are minimal (133). Aside from in vitro differentiated DCs, 
1,25(OH)2D3 also induces a tolerogenic phenotype in dermal 
DCs, Langerhans cells, and plasmacytoid DCs, even though there 
are subtle differences between the effects on these subsets (100, 
134, 135).
While the tolerizing effects of 1,25(OH)2D3 on DCs are well 
described, the underlying mechanisms are less clear. Recently, 
Ferreira et al. suggested that a metabolic switch toward glycolysis 
and activation of the PI3K-Akt-mTOR pathway are the first steps 
for the generation of tDCs by 1,25(OH)2D3 (101). Also the induc-
tion of indoleamine 2,3-dioxygenase (IDO) on DCs has been 
reported to be essential for the induction of a tDC phenotype 
and thereby for the beneficial effect of 1,25(OH)2D3 on EAE 
(102). Although all tDCs promote regulatory T cells (Tregs), the 
mechanism by which they do this depends on the type of DC. 
While tDC derived in  vitro from bone marrow cells promote 
Tregs via induction of herpesvirus entry mediator (HVEM), tol-
erized Langerhans cells use TGFβ for this (100, 103). Dermal DCs 
induce the differentiation of T regulatory 1 (Tr1) cells, another 
type of Treg, via IL-10 (100). So in recent years, advances have 
been made to fully understand how 1,25(OH)2D3 modulates DCs, 
but the picture is not yet complete.
Despite the incomplete understanding of the molecular mech-
anism behind the effects of 1,25(OH)2D3 on DCs, tDCs generated 
with 1,25(OH)2D3 alone or in combination with dexamethasone 
are considered for therapy in autoimmune diseases (136). Their 
persistent tolerogenic state and the possibility to pulse them with 
tissue-specific antigens have made them valuable candidates to 
treat various diseases, including autoimmune diseases (99, 132, 
137). This is illustrated in experimental disease models for T1D, 
MS, and RA, where administered antigen-specific tDCs migrate 
to inflammatory sites and reduce disease activity upon admin-
istration (102, 138–140). Importantly, DCs with an increased 
activation status from patients with autoimmune diseases can 
become equally tolerogenic in response to 1,25(OH)2D3 as 
healthy DCs (141–145). Because they can also be pulsed with 
auto-antigens and they can be generated under current Good 
Manufacturing Practice conditions, this opens up the way for 
the use of autologous tDCs in the treatment of human autoim-
mune diseases (141, 146). Currently, the use of tDCs generated 
with 1,25(OH)2D3 has not been clinically tested. However, tDCs 
generated using antisense oligonucleotides or Bay11-7082 were 
found to be safe upon administration in patients with T1D or RA, 
respectively (147, 148).
It remains to be determined whether these tDCs also have 
effects on disease activity and whether tDCs generated using 
1,25(OH)2D3 could also be used in this context. Increased under-
standing on how 1,25(OH)2D3, with or without dexamethasone, 
modulates the DCs can provide insights in how to further opti-
mize the tolerogenic potential of the DCs.
Macrophages
Macrophages are known for their supreme phagocytic capacities, 
but they are also important APCs. In a normal immune response, 
an infection activates tissue-resident macrophages after which 
they produce inflammatory mediators and recruit other immune 
cells to eradicate the pathogen. Macrophages can roughly be 
divided into two categories: the M1 and M2 macrophages. M1 
macrophages produce pro-inflammatory mediators like nitric 
oxide, TNFα, IL-23, IL-12, and IL-1β, whereby they kill pathogens 
and promote the polarization of T helper (Th) cells to T helper 
1 (Th1) and Th17 cells to assist in the immune response. On the 
other hand, M2 macrophages produce the anti-inflammatory 
cytokine IL-10 and are important in wound repair and restoring 
tissue homeostasis (149).
The role of macrophages in the pathogenesis of autoimmune 
diseases is illustrated by an increase in macrophages at inflamma-
tory sites (150–153). In addition, macrophages are hyperactivated 
and produce more pro-inflammatory cytokines, suggesting a 
dysregulated balance between M1 and M2 cells (104, 151, 154). 
As a result of their hyper-inflammatory state, they are essential for 
the development and activation of β-cell specific cytotoxic T cells, 
which leads to insulitis in NOD mice (155). Interestingly, the sup-
pression of EAE by 1,25(OH)2D3 is preceded by a rapid reduction 
of macrophages in the CNS. This suggests that macrophages are 
another important target for vitamin D in the suppression of 
autoimmunity (156).
Notably, 1,25(OH)2D3 has dual roles in macrophage differenti-
ation and activation. In the early stages of infection, 1,25(OH)2D3 
stimulates differentiation of monocytes into macrophages (157). 
Furthermore, toll-like receptor triggering or IFNγ-induced acti-
vation activates Cyp27B1 and thereby potentiates the conversion 
of 25(OH)D3 into 1,25(OH)2D3 (158, 159). 1,25(OH)2D3 obtained 
via this pathway is then required for producing cathelicidin and for 
the antimicrobial activity of human monocytes and macrophages 
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(160, 161). In addition, 1,25(OH)2D3 induces IL-1β, either directly 
or via upregulation of C/EBPβ or Erk1/2 (162, 163). So initially, 
1,25(OH)2D3 is essential for effective pathogen clearance.
The hyperresponsiveness of VDR−/− mice to LPS stimula-
tion indicates that in the later stages of infection, 1,25(OH)2D3 
plays a role in the contraction of the immune response (105). 
The anti-inflammatory effect of 1,25(OH)2D3 on macrophages 
is characterized by decreased production of pro-inflammatory 
factors such as IL-1β, IL-6, TNFα, RANKL, COX-2, and nitric 
oxide and increased anti-inflammatory IL-10 (104–108). These 
changes suggest that 1,25(OH)2D3 promotes the M2 phenotype 
while inhibiting the M1 phenotype, thereby restoring the balance 
between these subsets. Finally, 1,25(OH)2D3-treated macrophages 
have reduced T cell stimulatory capacity (108).
In recent years, some advances were made with unraveling the 
mechanism behind this anti-inflammatory effect of 1,25(OH)2D3 
on macrophages. An important target of 1,25(OH)2D3 is thioester-
ase superfamily member 4 (THEM4), an inhibitor of the NFκB 
signaling pathway. THEM4 inhibits the direct binding of NFκB 
to the COX-2 locus and thereby prevents COX-2 transcription 
(106). Furthermore, THEM4 inhibits IL-6 and TNFα expression 
by preventing the signaling cascade in which NFκB induces miR-
155 to suppress SOCS (105). Whether this THEM4-dependent 
pathway also inhibits the other pro-inflammatory mediators is 
not yet clear (104).
The balancing effect of 1,25(OH)2D3 between the pro- and 
anti-inflammatory status of macrophages is of particular inter-
est in the treatment of autoimmune diseases. Currently, many 
inflammatory mediators secreted by M1 macrophages, like IL-1β, 
COX-2, IL-6, and especially TNFα, are already successful thera-
peutic targets in various autoimmune diseases. However, since 
current therapies result in systemic reduction of these mediators, 
patients may become prone to infections. Therefore, it is of inter-
est to understand the mechanism by which 1,25(OH)2D3 balances 
between pro- and anti-inflammatory actions. This may provide 
insights in how to suppress the pro-inflammatory cytokines only 
in case of hyperactivation, without affecting the normal immune 
response.
B Cells
B cells are mostly known for their crucial role in the immune 
response via the differentiation toward plasma cells and the pro-
duction of antibodies. However, they also modulate the immune 
response via antigen presentation and cytokine secretion. In 
the context of autoimmunity, B cells play a crucial role by the 
production of autoreactive antibodies. These auto-antibodies, 
like anti-nuclear antibodies (ANAs) in SLE and anti-citrullinated 
peptide antibodies (ACPA) in RA, can be found in >95% and 70% 
of patients, respectively (164, 165).
Interestingly, the VDR binds to the promoter region of genes 
involved in the immune system in lymphoblastoid B cell lines, 
suggesting a role for B cells in the effect of vitamin D on autoim-
mune diseases (166). Here, we discuss what is known about the 
direct effects of 1,25(OH)2D3 on B cell differentiation and the 
three B cell functions of antibody production, cytokine secretion, 
and antigen presentation.
Before B cells become plasma cells that secrete high-affinity 
antibodies, they have to go through various stages of differen-
tiation, class-switch recombination and somatic hypermutation 
(167). Various reports indicate that 1,25(OH)2D3 reduces the pro-
liferation of B cells, induces their apoptosis and inhibits immuno-
globulin class switching (90–92). This inhibition of differentiation 
may involve preventing nuclear translocation of NF-κB p65 and 
thereby inhibiting the signaling pathway downstream of CD40 
costimulation (93). On the other hand, 1,25(OH)2D3 stimulates 
plasma cell development when added to terminally differentiating 
B cells. Furthermore, it induces the chemokine receptor CCR10 
on these plasma cells, promoting their migration toward mucosal 
sites of inflammation (168). Therefore, it appears that the effect of 
1,25(OH)2D3 depends on the activation and differentiation status 
of the B cells.
Independent of the effect of 1,25(OH)2D3 on B cell differen-
tiation, there is ample evidence that it decreases the antibody 
production (90–92, 94, 95). Interestingly, the presence of ANA 
is correlated with a lower serum 25(OH)D3 level even in healthy 
people without SLE (169), while cholecalciferol supplementation 
decreases auto-antibody titers (65, 109).
Next to antibody production, B cells also secrete cytokines 
to influence the inflammatory milieu. Interestingly, VDR binds 
directly to the promoter region of IL-10 in B cells, thereby induc-
ing the expression of IL-10 (75). However, in a cohort of healthy 
controls and relapsing-remitting MS patients, there was no cor-
relation between IL-10 producing B cells and serum 25(OH)D3 
levels (170).
There has been limited research toward the effect of 
1,25(OH)2D3 on the APC function of B cells. However one study 
suggested that B cells primed with 1,25(OH)2D3 have decreased 
CD86 surface expression. Thereby, these B cells are less potent 
stimulators of naïve T cell proliferation and cytokine produc-
tion (96).
Altogether, the effect of 1,25(OH)2D3 on B cells is still not 
completely clear. Currently, it is hypothesized that 1,25(OH)2D3 
inhibits the pathogenic function of B cells in autoimmunity by 
preventing plasma cell differentiation and thereby auto-antibody 
production, by inducing IL-10 production and by inhibiting the 
antigen presentation capabilities. However, the limited amount of 
studies warrants further research to support this hypothesis and 
what role these effects play in the suppression of autoimmunity 
by 1,25(OH)2D3.
T Cells
Historically, it was thought that DCs were the main target of vita-
min D and that effects observed on T cells were mediated via DCs. 
However, it has now become clear that upon activation, various T 
cell populations express the VDR, including CD4+ Th cells, CD8+ 
cytotoxic T cells, and TCRγδ cells (12, 87, 171). This makes the 
T cell another direct immunological target for 1,25(OH)2D3. The 
effects of 1,25(OH)2D3 on T cells include modulation of cytokine 
secretion and differentiation, but VDR is also required for the 
activation of T cell by propagating TCR signaling (77). Since T 
cells are proposed to play an important role in the pathogenesis 
of autoimmunity, we will discuss the effects of 1,25(OH)2D3 on 
the various T cell populations.
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CD4+ T Cells
CD4+ T cells are a heterogeneous group of cells, including Th1, 
Th2, Th17, and Treg cells. In the normal immune response, Th1 
cells are important for fighting intracellular pathogens, Th2 cells 
for helminth infections and Th17 cells for extracellular pathogens 
and fungi. On the other hand, Tregs mediate immunological 
tolerance against self-antigens and harmless foreign antigens 
such as food and intestinal microbiota. Furthermore, they con-
trol the immune response via various mechanisms, including 
the secretion of anti-inflammatory mediators such as IL-10 and 
TGF-β (172). However, in autoimmune diseases, T cells mediate 
an immune response against the body itself, suggesting either 
hyperactivation of the pro-inflammatory T cells or insufficient 
control by Treg cells, or both.
The importance of the T cells as a target of 1,25(OH)2D3 in 
experimental autoimmune diseases is illustrated by Mayne et al., 
who showed that 1,25(OH)2D3 is not able to suppress EAE when 
the VDR is absent in T cells (173). For these studies, they used the 
CD4-Cre system, resulting in VDR deficiency in both CD4+ and 
CD8+ T cells. However, in this disease model, CD4+ T cells are 
likely the prime 1,25(OH)2D3 target cells, since other studies show 
that in this model CD8+ T cells are dispensable for the effects 
of 1,25(OH)2D3 (174). Further strengthening the hypothesis that 
the suppression of EAE by 1,25(OH)2D3 is driven by modulation 
of CD4+ T cells, is the finding that 1,25(OH)2D3 prevents CD4+ 
Th cell migration into the CNS (175). Finally, VDR binding is 
enriched near SNPs associated with autoimmune diseases in 
human CD4+ T cells, suggesting that these cells are also impor-
tant in the effects of 1,25(OH)2D3 in human autoimmunity (8).
Because the effects of 1,25(OH)2D3 differ between the various 
CD4+ Th cell subsets (110), we will give an overview of the cur-
rent knowledge on how these individual subsets are modulated by 
1,25(OH)2D3 to suppress the autoimmune response.
Th1 and Th2 Cells
Classically, CD4+ T cells were subdivided into two classes: Th1 
and Th2 cells. Th1 cells are characterized by the expression of 
IFNγ and T-bet, while Th2 cells produce IL-4, IL-5, and IL-13 
and express the transcription factor GATA3. In the context of 
autoimmunity, it was long thought that Th1 cells mediate the 
disease pathogenesis, since mice lacking the transcription factor 
T-bet are protected against EAE (176). However, the discovery of 
Th17 cells, which will be discussed in the next section, and the 
finding that IFNγ is not required for induction of autoimmunity 
have led to a debate as to whether Th1 cells are important for 
autoimmune pathogenesis (177, 178). However, since adoptive 
transfer of myelin-specific IFNγ+ cells induces EAE (179), Th1 
cells may still play a role in the disease pathogenesis.
Within Th1 cells, some studies suggest that 1,25(OH)2D3 
inhibits IFNγ production when added at the first phases of dif-
ferentiation (111, 180). On the other hand, another study found 
no effects on IFNγ (110). This contradiction could be explained 
by the addition of exogenous IL-2 in the first two studies. Since 
1,25(OH)2D3 directly downregulates IL-2, exogenous IL-2 might 
be required for the inhibition of IFNγ by 1,25(OH)2D3 (181, 182). 
Although these studies indicate that 1,25(OH)2D3 modulates Th1 
cells under certain circumstances, given their relatively small 
role in autoimmune pathogenesis and the low expression of VDR 
compared to other CD4+ T cell subsets, it is unlikely that they 
play an important role in the suppression of autoimmunity by 
1,25(OH)2D3 (110, 112).
In contrast to Th1 cells, Th2 cells might be protective in Th17-
driven autoimmune diseases even though they are pathogenic in 
the development of asthma and allergies. Studies in experimental 
arthritis demonstrate that T cell-specific overexpression of 
GATA3 is protective in autoimmunity due to suppression of Th17 
responses (183). Interestingly, IL-4 is required for 1,25(OH)2D3 
to inhibit EAE, suggesting an important role for this cytokine in 
the effect of 1,25(OH)2D3 (88). In the same model, 1,25(OH)2D3 
induces GATA3 and its regulator STAT6. The functional rel-
evance of this upregulation is demonstrated in STAT6-KO mice, 
where 1,25(OH)2D3 is unable to inhibit EAE development (184). 
Altogether these studies suggest a role for Th2 induction in the 
immune suppression by 1,25(OH)2D3.
However, the data on the effect of 1,25(OH)2D3 on Th2 
cytokines like IL-4 seems contradictory. When naïve CD4+ T cells 
or the entire CD4+ T cell population are cultured without polariz-
ing cytokines, 1,25(OH)2D3 induces IL-4 and GATA3 (113, 114). 
Also, in PBMC of treatment-naïve early RA patients, where IL-4 
production is diminished, 1,25(OH)2D3 restores the IL-4 levels to 
the levels of healthy controls (115). However, when naïve CD4+ T 
cells, effector CD4+ T cells, or total CD4+ T cells are cultured in the 
presence of IL-4 to induce Th2 polarization, cellular IL-4 produc-
tion is unaffected or even inhibited by 1,25(OH)2D3 (111, 180). 
Also when patients are supplemented with cholecalciferol, there 
is no increased IL-4 production by their T cells (109, 116, 117). 
Combining these data leads to the hypothesis that 1,25(OH)2D3 
promotes Th2 differentiation and IL-4 production to assist in 
suppression of autoimmunity, but only when no sufficient IL-4 
is present. The mechanism behind the precise regulation of IL-4 
is of interest not only for treatment of autoimmunity but also 
of allergies and asthma where Th2 cytokines play an important 
pathogenic role.
Th17 Cells
In most autoimmune diseases, Th17 cells are considered to be 
important drivers of disease pathogenesis. Th17 cells are charac-
terized by production of cytokines such as IL-17A, IL-17F, TNFα, 
and GM-CSF and the transcription factor RORC2 (RORγt in 
mice). They can also be distinguished based on the expression of 
the chemokine receptor CCR6, which directs migration toward 
the chemokine CCL20. Their differentiation can be driven by 
TGFβ, IL-6, and IL-1β, but they require IL-23 to become patho-
genic Th17 cells (185). In 2003, two hallmark studies showed 
that IL-23, and not IL-12, is required for the induction of EAE 
and CIA (186, 187), suggesting an important role for the IL-23/
IL-17 immune pathway in the pathogenesis of autoimmune dis-
eases. Indeed, local IL-17A overexpression in mouse knee joints 
induces an arthritis-like phenotype with inflammation, bone 
erosions, and damaged cartilage (188). In EAE, the pathogenic 
cells appear to be the ex-Th17 cells, which now express IFNγ and 
T-bet, indicating the importance of Th17 plasticity in autoim-
mune diseases (189). In human autoimmunity, for example, in 
RA and SLE, levels of Th17 cells are elevated in the peripheral 
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blood and synovial fluid of patients and correlate with disease 
activity (190–192). Furthermore, specifically the CCR6+ memory 
Th cells, which include Th17 cells, are potent activators of synovial 
fibroblasts (190). We have previously shown that this interaction 
leads to a pro-inflammatory feedback loop with increased pro-
duction of IL-17A, IL-6, IL-8, and tissue-destructive enzymes. 
Via this mechanism, Th17 cells may contribute to local joint 
inflammation in RA (190). Combining the important role of Th17 
cells in autoimmunity and the beneficial effect of 1,25(OH)2D3 
on autoimmune diseases, it is hypothesized that 1,25(OH)2D3 
suppresses autoimmunity at least partially via the inhibition of 
Th17 activity.
In support of this hypothesis, the effect of 1,25(OH)2D3 on 
an experimental model for antiretinal autoimmunity depends 
on inhibiting Th17 activity (193). Also in  vitro 1,25(OH)2D3 
decreases expression of pro-inflammatory cytokines like IL-17A, 
IL-17F, and IL-22 in CD4+ T cells, CD4+ memory cells, or 
CD4+CCR6+ memory cells (115, 118–120). Functionally, this 
decrease in Th17 activity diminishes activation of synovial fibro-
blasts, thereby inhibiting the pro-inflammatory loop between 
these cell types (120). Interestingly, 1,25(OH)2D3 also inhibits the 
secretion of IL-17A and other Th17 cytokines in the presence of 
Th17-polarizing cytokines (119, 121).
1,25(OH)2D3 not only inhibits the activity of Th17 cells but 
also Th17 differentiation. When naïve CD4+ T cells are dif-
ferentiated toward the Th17 lineage in  vitro, the presence of 
1,25(OH)2D3 inhibits Th17-related cytokines and transcription 
factors such as IL-17A, IL-17F, RORC, and CCR6 (110, 112, 
122). Functionally, MOG-specific Th17 cells differentiated in the 
presence of 1,25(OH)2D3 are less capable of inducing EAE upon 
adoptive transfer (119). Aside from the decreased pathogenicity 
of the cells, this effect may also be due to a decrease in CCR6, 
the chemokine receptor required for migration to the CNS (123).
Although the inhibitory effect on Th17 activity is well 
described, the mechanisms behind it are less clear. First of all, 
Joshi et al. showed that the regulation of IL-17A can be mediated 
via direct binding of the VDR to the IL-17A promoter. VDR–
RXR complexes compete with NFAT for the binding sites in the 
promoter, after which they recruit RUNX1 and HDAC (histone 
deacetylase) to inhibit IL-17A gene expression (119). This com-
petition for the NFAT binding site also occurs at the promoter 
of IL-2, a known primary 1,25(OH)2D3 target gene, suggesting 
that this may be a general mechanism that also applies to other 
NFAT-regulated genes (181). Recruitment of HDAC indicates 
that epigenetic regulation is also important in the inhibition of 
IL-17A by 1,25(OH)2D3, especially given the relative epigenetic 
instability of the IL-17A gene locus (194). Aside from this direct 
regulation of IL-17A, other mechanisms have also been proposed. 
One study showed that CHOP is crucial for the inhibitory effect 
of 1,25(OH)2D3, while a second study indicated IRF8 to be impor-
tant (112, 122). Yet another study indicated that VDR forms a 
complex with VDR, RXR, HDAC2, and Smad3 to inhibit Smad7 
transcription, thereby preventing IL-17A production (124). Of 
note, TGFβ is the cytokine that induces Smad3 and Erk, leading 
to this inhibition of IL-17A, but it is also the cytokine responsible 
for inducing the VDR (121). How these mechanisms relate to 
each other remains to be investigated.
Th17.1 Cells
Before the discovery of Th17 cells, it was thought that Th1 cells, 
characterized by expression of IFNγ, T-bet, and CXCR3, were 
the major drivers of the autoimmune response. The finding that 
IL-23, and not IL-12, was required for experimental autoimmun-
ity, at first completely shifted the viewpoint toward Th17 cells as 
the pathogenic drivers of autoimmunity. However, lately more 
and more studies indicate that the subdivision into Th17 and Th1 
is not as linear as previously assumed. Upon stimulation by IL-12 
or TNFα, Th17 cells can become double producers of IL-17A and 
IFNγ or even shift toward high IFNγ production with little or 
no IL-17A. Since these latter cells still express CCR6 and RORC, 
together with T-bet and CXCR3, they are called non-classic 
Th1 or Th17.1 cells (195). Currently, it is hypothesized that the 
Th17.1 cells are more pathogenic than Th17 cells in autoimmune 
diseases, because they are enriched at the sites of inflammation in 
several diseases (196, 197).
Interestingly, we have shown that in CCR6+ cells, which 
includes Th17 and Th17.1 cells, 1,25(OH)2D3 reduces the 
frequency of IFNγ+, IL-17A+, and IFNγ+ IL-17A+ cells (120). 
This suggests that 1,25(OH)2D3 can inhibit Th cell pathogenicity 
in autoimmunity via the inhibition of Th17 and Th17.1 cells. 
A similar effect was found in the CD4+ T cells of SLE patients 
supplemented with 10,400 IU cholecalciferol for 6 months (198). 
Other supplementation studies have not addressed the combined 
or single expression of IFNγ and IL-17A, but the results on total 
IL-17A+ or total IFNγ+ cells are ambiguous (109, 116, 117).
Regulatory T Cells
In contrast to the pro-inflammatory Th subsets mentioned 
above, regulatory T cells, or Tregs, suppress the immune 
response. Tregs express FoxP3, the anti-inflammatory cytokines 
IL-10 and TGFβ, the inhibitory co-receptor CTLA4, and a 
high level of CD25. They exert immunomodulatory effects on 
other immune cells such as macrophages, DCs, CD8+ T cells, 
and also other CD4+ T  cells, thereby maintaining immune 
homeostasis. Their essential role in preventing autoimmunity 
is demonstrated in patients with a mutation in FoxP3. These 
patients are suffering from the IPEX syndrome, which is char-
acterized by massive autoimmunity (199). In the autoimmune 
diseases discussed here, it is hypothesized that an imbalance 
between pro-inflammatory T cells, such as Th17 or Th17.1, and 
Tregs underlies the immune pathogenesis. 1,25(OH)2D3 may 
act by restoring this balance and thereby restoring immune 
homeostasis.
Indeed, 1,25(OH)2D3 induces FoxP3+ Tregs in the spleen, 
lymph nodes, and spinal cord of EAE mice (119, 124). Additionally, 
without IL-10 or IL-10-mediated signaling, 1,25(OH)2D3 cannot 
inhibit EAE (200). In in vitro cultures of Tregs, either obtained via 
in vitro polarization or sorted from peripheral blood, 1,25(OH)2D3 
induces the production of IL-10, but not FoxP3 (114, 201, 202). 
Polarized Tregs express a higher level of Treg-associated markers 
such as CTLA4, PD1, and CD25 and their suppressive capacity 
is enhanced by 1,25(OH)2D3 (202). Also, the suppressive capacity 
of Tregs is positively correlated with the serum 25(OH)D3 level 
in MS patients (203). However, when sorted Tregs are used, 
1,25(OH)2D3 does not further enhance their suppressive capacity 
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(114, 201). This suggests that 1,25(OH)2D3 optimizes Treg func-
tion in order to suppress autoimmunity.
Interestingly, 1,25(OH)2D3 also induces IL-10 production 
when CD4+ cells are cultured under neutral conditions, and 
even further in the presence of Th17 polarizing cytokines. 
Furthermore, in these cultures, 1,25(OH)2D3 also induces FoxP3 
and CTLA4, while enhancing the suppressive capacity of the cells 
(113, 118, 119, 121, 122, 124, 125). Because 1,25(OH)2D3 inhibits 
Th17 polarization while inducing IL-10 in these cultures, it was 
postulated that 1,25(OH)2D3 may inhibit Th17 activity via IL-10 
induction. However, IL-10 is dispensable for the inhibition of 
IL-17A, suggesting that Th17 inhibition and Treg induction are 
two independent mechanisms of 1,25(OH)2D3 (110).
On a molecular level, three mechanisms have been proposed 
by which 1,25(OH)2D3 can stimulate a Treg-like phenotype even 
under Th17 polarizing conditions. First, the VDR can bind to 
three VDREs in the conserved non-coding sequence of the FoxP3 
promoter, thereby directly controlling FoxP3 transcription (119, 
125). The second mechanism is by reversing the inhibitory effect 
of Th17 polarizing cytokines on CTLA4, leading to upregulation 
of CTLA4 (121). Finally, 1,25(OH)2D3 induces the expression of 
IDO, which increases the number of Tregs (76). The latter finding 
is interesting, since IDO was also reported to be important for the 
induction of tDCs (see Dendritic Cells) (102), suggesting it might 
be a general target of 1,25(OH)2D3 in the immune system.
Although the in  vitro data demonstrate that 1,25(OH)2D3 
induces Treg cells, not all cholecalciferol supplementation stud-
ies find an effect on Tregs. Several studies suggest an increase in 
the proportion or number of Treg cells based on surface marker 
expression (109, 116, 204) or based on IL-10 production (50, 
117). However, another study did not find this induction in 
Treg cells (63), and Treg suppressive function is unaffected by 
cholecalciferol supplementation (117).
Overall, in CD4+ T cells, 1,25(OH)2D3 inhibits the pro-
inflammatory Th cell functions while stimulating Treg activity. 
These effects are observed under both healthy and pathogenic 
conditions, such as in patients with autoimmune diseases (201). 
Therefore, restoring the disturbed balance between effector T cells 
and Treg cells may underlie the beneficial effects of 1,25(OH)2D3 
on autoimmunity.
CD8+ Cytotoxic T Cells
In addition to CD4+ T cells, cytotoxic CD8+ T cells comprise the 
second important class within the T cells. These cells contribute to 
the immune response by inducing apoptosis in abnormal cells, for 
example, in case of infection or uncontrolled growth in cancer. In 
addition, they modulate other immune cells by secreting cytokines 
(205). Although the role of CD8+ T cells in autoimmune diseases 
is not as well characterized as the role of CD4+ T cells, various 
studies indicate that they play a role in disease pathogenesis. For 
example, myelin-specific CD8+ T cells induce EAE in mice, with 
characteristics of human MS that are not conferred by myelin-
specific CD4+ T cells (206, 207). Similarly, hsp60-specific CD8+ 
T cells induce autoimmune intestinal inflammation (208). More 
recently, it was shown that IL-17A+ CD8+ T cells are enriched in 
the synovial fluid of psoriatic arthritis patients. These cells do not 
express cytolytic markers, but their levels are positively correlated 
with markers of disease activity (209). Since CD8+ T cells have 
a higher expression of VDR than CD4+ T cells (171), CD8+ 
T cells may also be a target for 1,25(OH)2D3 in the suppression 
of autoimmunity.
Indeed, adoptive transfer of VDR−/− CD8+ T cells in Rag-
deficient mice induces intestinal inflammation. When VDR−/− 
IL-10−/− CD8+ T cells are transferred, the intestinal inflammation 
is even worse and leads to wasting disease (79). The increased 
proliferation of VDR−/− CD8+ T cells, even in the naive state, 
suggests that VDR-induced signaling is required for maintain-
ing quiescence of these cells. Thereby 1,25(OH)2D3 prevented 
hyperactivation of CD8+ T cells and subsequent autoimmune 
pathology in diseases such as CD (79). In addition to main-
taining quiescence, 1,25(OH)2D3 also inhibits the secretion of 
IFNγ and TNFα by activated CD8+ T cells (80). Finally, topical 
treatment with calcipotriol decreases the frequency of IL-17A+ 
CD8+ cells in psoriatic lesions, which is interesting in light of the 
correlations between these cells and disease activity in psoriatic 
arthritis (82, 209).
Aside from modulating the activity of the classical CD8+ T cells 
to reduce autoimmunity, 1,25(OH)2D3 is also important in the 
development of CD8αα+ T cells. CD8αα+ T cells are self-reactive 
cells that have a regulatory function by maintaining homeostasis 
in the gut. In VDR−/− mice, the number of these cells is reduced, 
which may explain the susceptibility of these animals to intestinal 
inflammation (81).
It is important to note that the effect of 1,25(OH)2D3 is not 
mediated via the CD8+ T cells in every autoimmune disease, since 
they were dispensable for the attenuation of EAE by 1,25(OH)2D3 
(174). However, it seems that in IBD and psoriatic arthritis, the 
CD8+ T cells are target for 1,25(OH)2D3. It will be of great interest 
to determine what the role of the CD8+ T cells is in the effect of 
1,25(OH)2D3 on other autoimmune diseases. This will not only 
provide insight into the mechanisms behind the effect of vitamin 
D but also about the differences in pathogenesis in the various 
autoimmune diseases.
Unconventional T Cells
Next to the traditional CD4+ and CD8+ T cells, there are also cells 
expressing the TCR but lacking both CD4 and CD8. These so-
called unconventional T cells have a less diverse TCR repertoire 
and they are not restricted to MHC class I or II. The unconven-
tional T cells include mucosal-associated invariant T (MAIT) 
cells, TCRγδ T cells and natural killer T (NKT) cells.
Although MAIT cells have been implicated to be suppressive 
in autoimmunity, as reviewed by Godfrey et  al. (210), there is 
currently no data available on the effect of 1,25(OH)2D3 on 
these cells.
TCRγδ T cells are rapid responders in the event of an infection 
with intracellular pathogens, due to their recognition of phos-
phoantigens. Interestingly, they are pathogenic in autoimmune 
models like EAE and CIA and they produce a wide range of pro-
inflammatory cytokines like IL-17A, IL-17F, GM-CSF, TNFα, 
and IFNγ (211). There is only one study that investigated the 
effect of 1,25(OH)2D3 on the pro-inflammatory activity of these 
cells. They demonstrated that TCRγδ T cells express the VDR 
upon activation. In response to 1,25(OH)2D3, the production 
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of IFNγ and the proliferation of these cells was inhibited (87). 
Currently, it is thought that the main pathogenic action of the 
TCRγδ T cells in autoimmunity is the secretion of IL-17A (211). 
Unfortunately, there are no data available yet that describe 
the effect of 1,25(OH)2D3 on this cytokine, or any of the other 
cytokines secreted by the TCRγδ T cells.
The last subset of unconventional T cells that will be discussed 
here are the NKT cells. They recognize glycolipid antigens and 
are thereby involved in the protection against a wide range of 
pathogens. Upon TCR stimulation, NKT cells can rapidly secrete 
various pro-inflammatory cytokines, including IL-4, IFNγ, and 
IL-17A. NKT cells can be divided into type I and type II NKT 
cells. Type I NKT cells are also called invariant NKT (iNKT) cells 
due to their invariant TCR. Type II NKT cells have a variable 
TCR and are therefore called the variant NKT cells. The exact 
role of NKT cells in the pathogenesis of autoimmune disease is 
not yet completely clear. They are pathogenic in CIA, but they are 
protective in EAE, T1D, and SLE (88, 212).
Interestingly, VDR is required in the thymus for the develop-
ment of functionally mature iNKT cells. Furthermore, the iNKT 
cells in VDR−/− mice are hyporesponsive to TCR stimulation 
(89). In addition, the protective effect of 1,25(OH)2D3 in EAE is 
partially dependent on iNKT cells, possibly via inducing IL-4 in 
these cells (88). These data suggest that 1,25(OH)2D3 promotes a 
suppressive function of iNKT cells. However, given the two-sided 
effect of iNKT cells in the different autoimmune diseases, further 
research is needed to fully examine the effect of 1,25(OH)2D3 
on iNKT cell activity and what this means for each individual 
disease.
innate Lymphoid Cells
Recently, a new group of cells became the center of attention in 
the field of immunology; the innate lymphoid cells (ILC). ILCs 
play an important role in tissue repair, tissue homeostasis, and 
the immune response against bacteria, viruses, and fungi. ILCs 
can be grouped into three classes as follows: (i) the group 1 ILCs 
(ILC1) that secrete IFNγ and depend on T-bet expression, (ii) the 
group 2 ILCs (ILC2) that secrete type 2 cytokines such as IL-5 and 
IL-13 and depend on GATA3, and (iii) the group 3 ILCs (ILC3) 
that secrete IL-17A and/or IL-22 and depend on RORC (213).
The ILC1s include natural killer cells, which have been known 
for a longer time and play a role in the clearance of viruses. Since 
viral triggers are thought to play a role in the initiation of some 
autoimmune diseases, the NK cells have been investigated for 
their role in this context. However, under some circumstances, 
NK cells are protective, while in others they can be pathogenic as 
recently reviewed by Poggi and Zocchi (214). Also the data on the 
effect of 1,25(OH)2D3 on NK cells are somewhat contradictory. In 
an NK cell line, 1,25(OH)2D3 induces the cytolytic killing capacity 
of NK cells (83), but this effect has not been found in healthy 
control peripheral blood (84, 85). However, when 1,25(OH)2D3 
is added during the in  vitro differentiation of NK cells from 
hematopoietic stem cells, the development of NK cells is impaired 
and their cytotoxicity and IFNγ production are reduced (84). 
Interestingly, 1,25(OH)2D3 specifically inhibits activation, cyto-
toxic capacity and pro-inflammatory cytokine production in 
overactivated NK cells in women with recurrent pregnancy losses 
(85). This supports a hypothesis in which 1,25(OH)2D3 is not a 
general inhibitor of the immune response, but rather a regulator 
of immune homeostasis. Therefore, it is of interest whether this 
abnormal NK activation is also seen in autoimmune diseases and 
can be modulated by 1,25(OH)2D3.
Based on their cytokine signature, it can be hypothesized that 
in the context of autoimmunity ILC3 cells play a role in disease 
pathogenesis. Indeed, an increase in ILC3 cells has been demon-
strated in the lesional skin of psoriasis patients (215, 216), in the 
inflamed intestine of CD patients (217), in the peripheral blood of 
MS patients (218), and in the gut, peripheral blood, bone marrow, 
and synovial fluid of patients with ankylosing spondylitis (219). 
Furthermore, ILC3 were shown to be responsible for experimen-
tal innate-induced colitis (220). Interestingly, in VDR-KO mice, 
which are susceptible for colitis, the levels of ILC1 and ILC3 are 
increased (86). On the other hand, calcipotriol treatment did not 
affect the frequencies of ILC subsets in psoriatic skin lesions after 
2 weeks (82).
Since the research into ILC has only started to expand in 
recent years, the effects of 1,25(OH)2D3 on these cells have 
not been investigated extensively. Current data suggest that 
1,25(OH)2D3 may also have anti-inflammatory effects on these 
cells, but more studies are required to distinguish the effects on 
the different subsets and its role in the protective effect of vitamin 
D in autoimmunity.
indirect immunomodulatory effects
In the previous sections, we discussed the direct modulatory 
effects of 1,25(OH)2D3 on various cells of the immune system. 
However, 1,25(OH)2D3 and the VDR also affect tissue-resident 
cells, such as hepatic and pancreatic stellate cells, and the 
inflammatory mediators that they secrete (221, 222). This 
indirect mechanism of immune modulation by 1,25(OH)2D3 is 
also relevant in autoimmune diseases. For example, in RA, the 
interaction between T cells and synovial fibroblasts contributes 
to disease pathogenesis (190). Therefore, it is also of interest to 
study the effect of 1,25(OH)2D3 on the tissue-resident cells in the 
context of autoimmunity.
Similar to the tissue-resident tissue cells in liver and pancreas, 
1,25(OH)2D3 also directly affects RA synovial fibroblasts. Not 
only is the IL-1β-induced production of tissue-degrading matrix 
metalloprotease 1 inhibited, also the infiltration capacity of RA 
fibroblasts is reduced upon treatment with 1,25(OH)2D3 (223). 
But this effect on tissue-resident cells is not only found in the 
synovial cells. It was also shown that the VDR is required for 
intestinal homeostasis by limiting the production of IL-6 by epi-
thelial cells through inhibition of the NFκB pathway (224). Finally, 
1,25(OH)2D3 also affects brain pericytes, which may be relevant 
for MS. The pericytes line the epithelial cells of blood vessels, and 
in the brain, they are important for maintaining the blood–brain 
barrier and neuron functioning. Brain pericytes cells produce 
less pro-inflammatory genes when exposed to 1,25(OH)2D3 
while upregulating anti-inflammatory genes. Interestingly, brain 
pericytes express Cyp27B1 upon stimulation with TNFα and 
IFNγ. This indicates that an inflammatory environment promotes 
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the conversion of 25(OH)D3 into 1,25(OH)2D3, which then can 
dampen the inflammation by modulating the pericytes (225).
Overall, the indirect effects of vitamin D and the VDR on 
immune cells via tissue-resident cells have been underexposed 
in the past years. However, if we truly want to understand the 
molecular mechanisms by which 1,25(OH)2D3 acts in autoim-
mune diseases, these effects are very important for future studies.
FUTURe DiReCTiONS
In this review, we have discussed the advancements that have 
been made regarding the clinical effects of vitamin D and the 
molecular mechanisms that underlie these effects. However, there 
is still a lot that is unclear at the moment, which will be subject of 
investigation in the coming years.
vitamin D Supplementation
Based on the current data on the effect of vitamin D supplementa-
tion, it is still not possible to draw conclusions about the added 
value for the treatment of autoimmunity. This is due to the low 
number of trials, small patient numbers and heterogeneity in trial 
setup. In order to determine the therapeutic value of vitamin D 
supplementation, there are two big open questions that need to 
be addressed.
First, it is important to assess what serum 25(OH)D3 level is 
required for a beneficial effect of vitamin D in autoimmune dis-
eases. Based on the requirements for calcium homeostasis, current 
guidelines indicate that a level below 50 nmol/L corresponds with 
deficiency, between 50 and 74 nmol/L as insufficiency and above 
75 nmol/L as a sufficient 25(OH)D3 level (226, 227). However, 
in the context of autoimmunity, it is not known whether it is 
enough to correct deficiency or whether we should strive for an 
even higher serum 25(OH)D3 level. Using 75 nmol/L as a cut-off 
point, Raftery et al. showed that CD patients with sufficient serum 
25(OH)D3 have significantly higher quality of life and less severe 
disease as measured by intestinal permeability, LL-37 expression, 
and CDAI (59). Furthermore, in healthy individuals, the serum 
25(OH)D3 level is correlated with number of VDR binding sites in 
CD4+ T cells. When they have a level above 75 nmol/L, the VDR 
binding is enriched near genes associated with autoimmune dis-
eases and Tregs (8). However, clinical trials, either with or without 
placebo controls, do not consistently find immune modulation 
regardless of the baseline and endpoint serum 25(OH)D3 level 
(Table 2). It should be noted that these measurements have been 
done in the peripheral blood or in cells from the peripheral blood, 
which is not the site of inflammation and therefore may not be the 
most relevant place to look for immunological effects.
The second question that is still matter of debate is in what 
form and dosage vitamin D should be supplemented. In the 
experimental autoimmune models, animals are mostly supple-
mented with a high dose of 1,25(OH)2D3, but in humans, this 
strategy may lead to hypercalcemia. Therefore, most clinical 
trials use cholecalciferol as the form of choice, although some 
use 1,25(OH)2D3 or less calcemic analogs like alfacalcidol. Of 
note, a study comparing the effects of alfacalcidol [analog for 
1,25(OH)2D3] with colecalciferol (analog for cholecalciferol) 
indicates that in the short term alfacalcidol might be more effec-
tive, but this effect disappears after 12  months (232). Analogs 
like calcipotriol that are used in the topical treatment of psoriasis 
have not been tested in the other autoimmune diseases that 
were discussed here. Other analogs have been developed, which 
show equal or better immunomodulatory potential and have 
been successfully used in experimental autoimmune diseases 
(201, 233–237). The only analog that was used in clinical trials 
was alfacalcidol, mainly in type 1 diabetes patients (Table  1). 
However, the effects of alfacalcidol do not seem better than cal-
citriol, and at the same dosage, there were no severe side effects 
from either alfacalcidol or calcitriol (61, 62, 64). More research 
into the actual effects of vitamin D analogs on human autoim-
mune disease is required for establishing whether these analogs 
can be used safely and effectively. Furthermore, in the clinical 
trials performed so far, there were no serious adverse events 
after cholecalciferol supplementation. Therefore, it is important 
to establish the added value of the vitamin D analogs compared 
to cholecalciferol supplementation. Currently, cholecalciferol is 
the most used supplementation form in clinical practice. Vitamin 
D supplementation guidelines indicate a maximum safe dose of 
4,000  IU cholecalciferol/day for healthy adults (226). However, 
no adverse effects were found with dosages of up to 50,000 IU 
cholecalciferol weekly for 12  weeks, or 100,000  IU weekly for 
1 month followed by 100,000 IU monthly for 5 months (54, 109, 
117). Interestingly, the dose-escalation regime used by Burton 
et  al. and 20,000  IU weekly by Smolders et  al. did not elicit 
hypercalcemia despite reaching a serum 25(OH)D3 level of 400 
and 380 nmol/L, respectively (49, 117).
In considering the best strategy for cholecalciferol supplemen-
tation, it should also not be forgotten that 1,25(OH)2D3 may have 
a synergistic effect with other treatments. For example, in vitro 
studies have shown that 1,25(OH)2D3 synergizes with retinoic 
acid (an active vitamin A metabolite) or dexamethason in the 
inhibition of Th17 pathogenicity (115, 238). Also in monocytes, 
the combination of dexamethasone and 1,25(OH)2D3 has 
added effects over the compounds separately, partially because 
1,25(OH)2D3 enhances the effects of the glucocorticoid recep-
tor (239, 240). Furthermore, we have previously shown that 
1,25(OH)2D3 has an added effect on TNFα blockade in inhibiting 
the pro-inflammatory loop between Th17 cells and RASF in 
RA, suggesting that vitamin D combined with anti-TNFα could 
yield a better treatment response in the treatment of RA patients 
(120). Finally, combining 1,25(OH)2D3 with lovastatin has an 
added therapeutic effect on EAE. This is due to the inhibition 
of RhoA-ROCK signaling in autoreactive T cells, leading to 
decreased expression of Cyp24A1 and thereby less inactivation 
of 1,25(OH)2D3 (241). Altogether, these data indicate that it may 
be worthwhile to investigate the addition of cholecalciferol to 
current treatments like anti-TNFα, or to combine cholecalciferol 
with, for example, retinoic acid or statins. Due to the synergy 
between 1,25(OH)2D3 and these already approved drugs, a lower 
dose of cholecalciferol may be sufficient for achieving beneficial 
clinical effects.
Currently, several clinical trials are ongoing and recruiting 
patients in MS (http://clinicaltrials.gov identifier NCT01490502), 
RA (NCT02243800), and IBD (NCT02704624, NCT01046773, 
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TABLe 2 | Overview of clinical trials looking at immunological parameters after vitamin D supplementation.
Trial Disease Supplementation 
strategy
Mean baseline 
25(OH)D3
Mean endpoint 
25(OH)D3
PBMC T cells B cells innate immune 
cells (dendritic 
cell, NK)
Cytokines and 
antibodies 
in serum or 
plasma
CD4+ CD8+
Bock et al. 
(204)
Healthy 3 months 
140,000 IU 
cholecalciferol 
monthly or placebo
64 ± 29 nmol/L ~138 nmol/L Increased% of Tregs
Smolders 
et al. (117), 
Knippenberg 
et al. (170), 
Peelen  
et al. (182)
Multiple 
sclerosis  
(MS)
12 weeks 20,000 IU 
cholecalciferol daily 
(no placebo group)
50 (31–175) 
nmol/L
308 (151–535) 
nmol/L
No difference in 
% or function of 
Tregs, either naive or 
memory.
No relation between 
% IL-10+ or IL-17+ 
CD8+ and serum 
25(OH)D3
No difference 
in %, # or 
differentiation 
status of 
circulating B 
cells
No difference in 
BAFF
No change in 
immunoglobulins
Increased production 
of IL-10 and 
decreased IL-17A/ 
IL-4 ratio in T cells 
from PBMC cultures
No change in% 
IL-10+ or IL-17+ 
CD8+
Kimball  
et al. (228)
MS Dose escalation: 
up to 280,000 IU/
week in 23 weeks, 
stay 6 weeks, 
then reduce to 0 
in 20 weeks, then 
3 weeks without 
[trial: Burton  
et al. (49)]
78 ± 27 nmol/L 179 ± 76 nmol/L Decreased PBMC 
proliferation 
in response 
to certain 
MS-associated 
antigens
Mosayebi 
et al. (50)
MS 6 months 
300,000 IU 
cholecalciferol or 
placebo i.m. monthly
~25 nmol/L ~140 nmol/L Decreased PBMC 
proliferation upon 
PHA stimulation.
No difference in 
IFNγ, but increase 
in IL-10 and TGFβ 
production in 
these cultures
Sotirchos 
et al. (198)
MS 6 months 
10,400 or 800 IU 
cholecalciferol daily
10,400: 
68 ± 22 nmol/L
10,400: +87 
(63–112) nmol/L 
compared to 
baseline
High dose, but not 
low dose, decreases 
% IL-17+, but not 
% IFNγ+ or % IFNγ+ 
IL-17+
High dose, but 
not low dose, 
decreases CD85j+
(Continued)
Trial Disease Supplementation 
strategy
Mean baseline 
25(OH)D3
Mean endpoint 
25(OH)D3
PBMC T cells B cells innate immune 
cells (dendritic 
cell, NK)
Cytokines and 
antibodies 
in serum or 
plasma
CD4+ CD8+
800: 
70 ± 21 nmol/L
800: +17 (3–34) 
nmol/L compared 
to baseline
High dose, but not 
low dose, decreases 
% of EM and CD161+, 
while decreasing % 
of CM and naïve
% IL-17+ is 
correlated with % EM
For every 
12.5 nmol/L increase 
in serum 25(OH)D3, 
the % IL-17+ CD4+ 
decreases by 1% 
(when serum 25(OH)
D3 increases more 
than 45 nmol/L)
Bendix-
Struve et al. 
(229), Bartels  
et al. (143)
Crohn’s disease  
(CD)
1 year placebo 
vs. 1,200 IU 
cholecalciferol daily 
[trial Jørgensen  
et al. (57)]
33 (16–66) nmol/L 118 (62–154) 
nmol/L
Over time decrease 
of IL-6 production 
is prevented upon 
supplementation
Increased CD4+ 
proliferation is 
inversely correlated 
with the IL-10 
production
MoDCs have 
decreased IL-10, 
IL-6, IL-8, and 
IL-1β, CD80, 
and HLA-DR.
The allogeneic 
stimulatory 
capacities of 
moDCs are 
unaffected
Yang  
et al. (230)
CD 24 weeks, start 
with 1,000 IU 
cholecalciferol 
daily, increase to 
5,000 IU daily or 
until serum 25(OH)
D3 is 100 nmol/L (no 
placebo group)
40 ± 25 nmol/L 113 ± 48 nmol/L No change in 
IL-17, TNFα, or 
IL-10
Gabbay  
et al. (63)
T1D 18 months 2,000 IU 
cholecalciferol daily 
or placebo
66 ± 16 nmol/L 152 ± 54 nmol/L No change in % 
Tregs
No difference 
in IL-12, TNFα, 
CXCL10, or 
IL-10, but close-
to-significant 
increase of CCL2 
after 12 months 
(not after 
18 months)
TABLe 2 | Continued
(Continued)
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Trial Disease Supplementation 
strategy
Mean baseline 
25(OH)D3
Mean endpoint 
25(OH)D3
PBMC T cells B cells innate immune 
cells (dendritic 
cell, NK)
Cytokines and 
antibodies 
in serum or 
plasma
CD4+ CD8+
Terrier  
et al. (109)
Systemic lupus 
erythematosus 
(SLE)
4 weeks 100,000 IU 
cholecalciferol 
weekly, then 
6 months 
100,000 IU monthly 
(no placebo group)
47 ± 17 nmol/L 129 ± 35 nmol/L No change in total 
% or #
No change in total% 
or #.
Decrease in 
% and # after 
2 months, but 
after 6 months 
only in %
Increase 
in MZ% 
and # after 
6 months.
Decrease in % 
and # DN after 
6 months.
No change in 
naive or CS B 
cells
No change in % 
or # of NK cells
Anti-dsDNA 
decreased
Increase in # naive at 
6 months, but not %. 
No change in other 
activation stages
Decrease in % 
effector memory at 
2 and 6 months, 
but not #.
Increase in % and # 
of Tregs, aTregs, and 
rTregs.
No change in other 
activation stages
Increase of % 
CTLA4+ and GITR+, 
but not LAP+ Tregs
Decrease in IFNγ+ 
at 2 months
Decrease in % of 
Th1 and Th17 at 
2 months, but only of 
Th1 at 6 months. No 
change in Th2
Abou-Raya 
et al. (65)
SLE 12 months placebo 
vs. 2,000 IU 
cholecalciferol daily
50 ± 41 nmol/L 95 ± 41 nmol/L Decrease in 
IL-1β, IL-6, 
IL-18, and TNFα
Decrease in anti-
dsDNA, anti-Sm, 
and C4, but not 
anticardiolipin 
IgG or IgM
Piantoni 
et al. (116), 
Andreoli  
et al. (231)
SLE 12 months 
25,000 IU 
cholecalciferol 
monthly (standard 
regime, SR) or 
300,000 IU at 
baseline followed by 
50,000 IU monthly 
(intensive regime, 
IR), compared with 
healthy control 
immune parameters
SR: 79  
(20–211) nmol/L
IR: 80 (47–188) 
nmol/L
SR: 68 nmol/L
IR: 96 nmol/L
Upon SR increase 
in % and [ ] of iTreg 
but not tTreg. In IR 
increased % iTreg 
and % tTreg, but 
not [ ].
In SR and IR 
increase in [ ] highly 
experienced Tmem, 
but only in % in SR
Increase in total 
CD4% in SR and IR, 
but only in [ ] in IR
No change in % of 
IL-17+, IFNγ+, or 
IL-4+ CD4+ T cells 
after SR and IR
Increase in % but 
not [ ] of CD8+ in SR 
and IR.
No change in % 
of IL-17+, IFNγ+, 
or IL-4+ CD8+ 
cells after both SR 
and IR, but in IR a 
decreased IFNγ/
IL-4 ratio
No difference 
in anti-dsDNA 
between SR 
and IR
aTreg, activated memory regulatory T cells; BAFF, B-cell activating factor; CM, central memory; CS, class-switched memory; DN, double negative; EM, effector memory; iTreg, induced regulatory T cells; IU, international units; moDC, 
monocyte-derived dendritic cell; MZ, marginal zone; rTreg, resting regulatory T cells; TE, terminal effector; tTreg, thymic regulatory T cells; #, number; [ ], concentration.
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NCT02208310) for which the results are expected in the com-
ing 3–5  years. Hopefully, they can provide more insight into 
the answers on these remaining questions. However, to firmly 
establish the added value of cholecalciferol supplementation, 
large multicenter trials are required. Ideally, in these trials, the 
patients should be randomized into different treat-to-target arms, 
in which every arm has a target 25(OH)D3 serum level, such as 75, 
100, and 150 nmol/L. Since the effect of cholecalciferol alone is 
probably not sufficient to control disease activity, patients should 
receive standard care following pre-defined, harmonized treat-
ment protocols in addition to the cholecalciferol supplementation.
Molecular Mechanisms Underlying 
immunomodulation
In addition to the studies where cholecalciferol has been supple-
mented, attention has also focused on understanding the immu-
nomodulatory effects of 1,25(OH)2D3 on a cellular level. Based on 
the current knowledge, 1,25(OH)2D3 reduced the pathogenicity 
of DCs, macrophages, CD4+ T cells, CD8+ T cells, and B cells. 
Similar effects have been observed in γδ T cells, iNKT cells, and 
ILCs, but more research is necessary to confirm these data (see 
section 5). It should be noted that 1,25(OH)2D3 does not merely 
work as an anti-inflammatory agent. Instead, 1,25(OH)2D3 assists 
in maintaining the balance between a pro- and anti-inflammatory 
state and is thereby able to restore the disturbed balance that is 
associated with autoimmunity.
This balancing effect of 1,25(OH)2D3 is best illustrated in 
monocytes and macrophages, where it has pro-inflammatory 
effects in the early stages of activation but later shifts to an anti-
inflammatory state (242). Therefore, it is interesting to study 
the effects of 1,25(OH)2D3 in more detail in the various stages 
of differentiation and activation from monocyte to macrophage. 
The Carlberg lab has performed ChIP-seq experiments in the 
monocytic THP-1 cell line at early time points (5). Detailed stud-
ies have revealed several primary target genes such as ASAP2 and 
THBD (243–245), but also identified Bcl6 as a primary target 
that mediates important secondary responses (246). Next to the 
primary target genes, combining the ChIP-seq dataset with publi-
cally available ChIA-PET and FAIRE-seq datasets has improved 
the knowledge on VDR binding kinetics (247, 248).
This is just an example of how next-generation sequencing 
techniques can be combined to yield more understanding of the 
molecular mechanisms behind the effects of 1,25(OH)2D3. Since 
it has already been shown that 1,25(OH)2D3 has different effects 
on every cell type, even closely related cell types such as Th1 and 
Th17 (110), it will be interesting to study VDR DNA binding 
and identify primary target genes in separate cell types. This 
will give insight into the similarities and differences between the 
effects of 1,25(OH)2D3 on each cell, and what will be important 
to balance the immune response in patients with autoimmune 
diseases.
CONCLUSiON
Although various studies have shown a beneficial effect of 
cholecalciferol supplementation in autoimmune diseases, there 
are also studies that do not find any effect on disease parameters. 
This might be due to the supplementation strategy or the subjects 
included in the study, which are issues that should be addressed 
in properly designed multicenter clinical trials.
However, it is also possible that systemic cholecalciferol 
supplementation is not sufficient to establish effects in every 
patient. Therefore, another way to use the immunomodulatory 
effects of vitamin D to the advantage of patients with autoim-
mune diseases is to mimic the effects by targeting important 
pathways within immune cells. In order to do this, it is crucial 
to understand the working mechanisms of 1,25(OH)2D3. In the 
coming years, attention should be paid toward unraveling these 
molecular mechanisms to optimize the therapeutic potential of 
vitamin D.
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